INTRODUCTION: Harnessing the power of molecular imaging in particular positron emission tomography (PET) to assess response to therapy in early clinical trials has the potential to yield crucial data on efficacy and streamline drug development. Vorinostat (also known as SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor which alters gene transcription to inhibit proliferation and promote apoptosis. METHODS: In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. FDG-PET/CT fuses the power of metabolic imaging from FDG-PET with the anatomic detail of CT. Scans were conducted on subjects pre-therapy and during therapy. RESULTS: Changes in the values of FDG uptake and measurements of nodal dimensions and thickness of cutaneous lesions were tabulated. FDG-PET/CT provided an objective measure of the response (or lack thereof) of both cutaneous and nodal disease to therapy with vorinostat. The results of this study are encouraging for the potential utility of FDG-PET/CT in future trials with HDAC inhibitors for other diseases and for CTCL with other therapies. CONCLUSION: Further study will be required to determine the prognostic value of the initial PET/CT scan and response on follow-up scans.
INTRODUCTION: Harnessing the power of molecular imaging in particular positron emission tomography (PET) to assess response to therapy in early clinical trials has the potential to yield crucial data on efficacy and streamline drug development. Vorinostat (also known as SAHA, suberoylanilide hydroxamic acid) is a histone deacetylase (HDAC) inhibitor which alters gene transcription to inhibit proliferation and promote apoptosis. METHODS: In a phase II trial of vorinostat for cutaneous T cell lymphoma (CTCL), 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET/computed tomography (CT) was performed on patients with both cutaneous and nodal disease. FDG-PET/CT fuses the power of metabolic imaging from FDG-PET with the anatomic detail of CT. Scans were conducted on subjects pre-therapy and during therapy. RESULTS: Changes in the values of FDG uptake and measurements of nodal dimensions and thickness of cutaneous lesions were tabulated. FDG-PET/CT provided an objective measure of the response (or lack thereof) of both cutaneous and nodal disease to therapy with vorinostat. The results of this study are encouraging for the potential utility of FDG-PET/CT in future trials with HDAC inhibitors for other diseases and for CTCL with other therapies. CONCLUSION: Further study will be required to determine the prognostic value of the initial PET/CT scan and response on follow-up scans.
Authors: Julia Valencak; Alexander Becherer; Manon Der-Petrossian; Franz Trautinger; Markus Raderer; Martha Hoffmann Journal: Haematologica Date: 2004-01 Impact factor: 9.941
Authors: Madeleine Duvic; Rakshandra Talpur; Xiao Ni; Chunlei Zhang; Parul Hazarika; Cecilia Kelly; Judy H Chiao; John F Reilly; Justin L Ricker; Victoria M Richon; Stanley R Frankel Journal: Blood Date: 2006-09-07 Impact factor: 22.113
Authors: Eunice Y Tsai; Alan Taur; Leandro Espinosa; Andrew Quon; Denise Johnson; Sarah Dick; Steve Chow; Ranjana Advani; Roger Warnke; Sabine Kohler; Richard T Hoppe; Youn H Kim Journal: Arch Dermatol Date: 2006-05
Authors: Phillip H Kuo; Bruce L McClennan; Kacie Carlson; Lynn D Wilson; Richard L Edelson; Peter W Heald; Michael Girardi Journal: Mol Imaging Biol Date: 2008-01-15 Impact factor: 3.488
Authors: Michael Shapiro; Mijin Yun; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Norman Schulman; Bruce H Saidman; Richard G Fried; Alain H Rook; Abass Alavi Journal: J Am Acad Dermatol Date: 2002-10 Impact factor: 11.527
Authors: Xin Gao; Zhong Xue; Jiong Xing; Daniel Y Lee; Stephen M Gottschalk; Helen E Heslop; Catherine M Bollard; Stephen T C Wong Journal: Acad Radiol Date: 2010-01-12 Impact factor: 3.173